In the news
October 29, 2025
Targeting Iron in Dry AMD
The Ophthalmologist.
READ MORE >
October 28, 2025
Research supports that iron dysregulation may drive AMD
Ophthalmology Times
READ MORE >
October 15, 2025
PulseSight Therapeutics Publishes Data Supporting Transferrin Therapy for Dry AMD and Geographic Atrophy
OBN
READ MORE >
September 15, 2025
PulseSight Therapeutics Builds Non-Viral Gene Therapy Pipeline For AMD
Scrip
READ MORE >
September 5, 2025
Study Connects Iron Regulation and Vision Loss
Ophthalmology Management
READ MORE >
September 4, 2025
Study Connects Iron Regulation and Vision Loss
Retinal Physican
READ MORE >
September 4, 2025
PulseSight to highlight new data on the role of iron and transferrin in AMD at EURETINA 2025
Modern Retina
READ MORE >
September 4, 2025
PulseSight Therapeutics to Present New Data on Iron Dysregulation and Ferroptosis in AMD at Euretina 2025
Eyewire
READ MORE >
August 15, 2025
A new treatment for dry AMD and tackling peanut allergies
Base to Base biotech podcast 22
READ MORE >
July 8, 2025
PulseSight doses first subject in Phase I trial of dry AMD/GA therapy
Clinical Trials Arena
READ MORE >
July 7, 2025
PulseSight Begins Dry AMD Trial
Retinal Physician
READ MORE >
July 7, 2025
First Patient Dosed in Phase 1 Clinical Trial of PulseSight Therapeutics’ Treatment for Dry AMD, GA
Ophthalmology Management
READ MORE >
July 7, 2025
PulseSight Therapeutics Reports First Patient Dosing with PST-611 in P-I (PST-611-CT1) Trial for Dry AMD/Geographic Atrophy
PharmaShots
READ MORE >
July 7, 2025
First patient dosed in trial for novel dry AMD treatment PST-611
Pharma Times Online
READ MORE >
July 7, 2025
PulseSight launches first-in-human trial of AMD gene therapy
Longevity Technology
READ MORE >
May 14, 2025
Crossing the Cell Membrane Without Viruses
GEN
READ MORE >
April 16, 2025
PulseSight Therapeutics: Nonviral Gene Therapy for Dry AMD
Med Tech Strategist
READ MORE >
February 20, 2025
PulseSight Therapeutics SAS receives funds to support clinical trials of PST-611
Modern Retina
READ MORE >
February 14, 2025
PulseSight Therapeutics closes Series A financing for dry AMD phase 1 clinical study
Pharmafile
READ MORE >
February 13, 2025
PulseSight closes first Series A financing
The Pharma Letter
READ MORE >
January 16, 2025
PulseSight Therapeutics submits Clinical Trial Authorisation for phase I trial of PST-611
European Ophthalmology Times
READ MORE >
January 14, 2025
Pulsesight seeks clinical trial clearance for PST-611 for dry AMD/geographic atrophy
BioWorld
READ MORE >
November 11, 2024
Data support transferrin vectorised therapy for geographic atrophy
Drug Discovery World
READ MORE >
April 9, 2024
PulseSight Therapeutics Establishes International Scientific and Clinical Advisory Board
Eyewire
READ MORE >
March 4, 2024
PulseSight launches with gene therapy platform targeting age-related blindness
Longevity Technology
READ MORE >
February 29, 2024
PulseSight Therapeutics launches with focus on non-viral gene therapies
Healio
READ MORE >
February 29, 2024
PulseSight to disrupt AMD space
European Biotechnology Life Sciences
READ MORE >
February 28, 2024
PulseSight Therapeutics Launches With Age-Related Macular Disease Gene Therapy Pipeline
Precision Medicine Online
READ MORE >
February 28, 2024
PulseSight Therapeutics launches to advance non-viral gene therapies
Manufacturing Chemist
READ MORE >
February 28, 2024
[Funding alert] Paris-based PulseSight Therapeutics Secures an Undisclosed Amount in Seed Funding
StartUpRise EU
READ MORE >
February 28, 2024
PulseSight Therapeutics launches to advance non-viral gene therapies
Pharma Letter
READ MORE >
February 28, 2024
Launch of PulseSight Therapeutics: advancing non-viral gene therapy for eye diseases
Pharmaceutical Daily
READ MORE >
February 28, 2024
PulseSight Therapeutics Will Develop Next Generation Eye Gene Therapies
Inside Precision Medicine
READ MORE >
February 28, 2024
PulseSight unveils minimally invasive gene therapies for eye diseases
Live Forever Club
READ MORE >